Functional heterogeneity of ryanodine receptor mutations associated with sudden cardiac death

N Lowri Thomas1, Christopher H George, F Anthony Lai

  • 1Department of Cardiology, Wales Heart Research Institute, University of Wales College of Medicine, Heath Park, Cardiff, Wales CF14 4XN, UK.

Cardiovascular Research
|September 15, 2004
PubMed
Abstract

Insights

Mutations in cardiac ryanodine receptor (RyR2) linked to sudden cardiac death (SCD) show varied effects on calcium release. Some RyR2 mutations increase calcium levels, potentially complicating therapies for stress-induced ventricular tachycardia (VT).

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Genetics

Background:

  • Point mutations in the cardiac ryanodine receptor (RyR2) are linked to abnormal intracellular calcium (Ca2+) release.
  • These RyR2 mutations are associated with stress-induced ventricular tachycardia (VT) and sudden cardiac death (SCD).
  • The exact molecular mechanisms of RyR2 dysfunction in SCD are debated, but mutations are thought to increase Ca2+ release.

Purpose of the Study:

  • To investigate the functional impact of specific SCD-linked RyR2 mutations (L433P, N2386I, R176Q/T2504M) on intracellular Ca2+ handling.
  • To characterize the Ca2+ release properties of these RyR2 mutants in a cellular model.

Main Methods:

  • Full-length recombinant human wild-type (WT) and SCD-linked RyR2 mutations were expressed in human embryonic kidney (HEK) cells.
  • Caffeine-evoked Ca2+ release through homo-tetrameric channels was profiled in living cells using rapid confocal laser scanning microscopy.

Main Results:

  • SCD-linked RyR2 mutations displayed heterogeneous Ca2+ release profiles compared to WT channels.
  • One mutant, L433P, showed a reduced sensitivity to channel activation.
  • All characterized SCD-linked RyR2 mutations resulted in a prolonged elevation of cytoplasmic Ca2+ levels after channel activation.

Conclusions:

  • Live cell data reveal functional heterogeneity in Ca2+ release through SCD-linked RyR2 mutants.
  • The underlying mechanisms of RyR2 dysfunction in SCD may be more complex than previously assumed.
  • Findings could impact therapeutic strategies for stress-induced VT and SCD targeting RyR2.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...